Navigation Links
Champions Oncology Clarifies Misstatements in News Article
Date:7/18/2011

BALTIMORE, July 18, 2011 /PRNewswire/ -- Champions Oncology, Inc., formerly Champions Biotechnology, Inc. (OTC: CSBR) released the following statement to correct errors which recently appeared in Hebrew in the Israeli biotechnology business press and which came to the Company's attention on July 16, 2011:

"Recently, a Hebrew language business news service reported that Champions has agreed to create a subsidiary which will be used by Champions for the development of a drug compound that we have in-licensed.  Contrary to this news report, the Company has not made any final determination with respect to the future development of this drug compound."

As the Company stated in our Annual Report on Form 10-K for our fiscal year ended April 30, 2011 (filed on July 15, 2011):

Historically, our strategy was to use our technology platform to identify promising compounds that could be in-licensed during the preclinical phase.  The strategy was to invest in the clinical development of these compounds and then seek a partner that would bring them to market in exchange for some combination of upfront payments, milestone payments and royalties on sales.  Since 2007, the company pursued this strategy with four compounds.  All four of these compounds were subjected to Tumorgraft testing, and the results of one of the compounds warranted further investment.  During 2011, we changed our strategy and no longer intend to in-license additional compounds.  We have refocused the Company on developing advanced technologies to personalize the development and use of oncology drugs.  We intend to continue the development of the compound which warranted further investment and we are seeking a partner to finance the future development of the product.

We are working to assess potential financing alternatives for developing this compound, including the appropriate structure and valuation.  We do not yet have the information nee
'/>"/>

SOURCE Champions Oncology, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Champions Oncology Reports Full Year 2011 Financial Results
2. Champions Oncology (formerly Champions Biotechnology) Completes $9.4 Million Financing
3. Champions Biotechnology Changes Name to Champions Oncology
4. Champions Announces Technology Collaboration Utilizing Champions Tumorgraft™ Technology Platform for Oncology Drug Development
5. Champions Biotechnology Reports Fiscal 2011 Third Quarter Financial Results
6. Champions Biotechnology Reports Additions to its Management Team
7. Champions Biotechnology Reports Fiscal 2011 First Quarter Financial Results
8. Champions Biotechnology Reports Fiscal 2010 Third Quarter Financial Results
9. Champions Biotechnology Enters into Licensing Agreement with Yale University and Southern Research Institute for the Repurposing of Bithionol for Oncology
10. Champions Biotechnology to Present Data at AACR-EORTC 2009 Regarding the Predictability of Biomerk Tumorgraft(TM) Platform to Guide Personalized Cancer Treatment and Accelerate Oncology Drug Development
11. Champions Biotechnology Expands Collaboration to Test Oncology Therapeutic in Biomerk Tumorgrafts(TM)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/7/2015)... (PRWEB) , ... July 07, 2015 , ... ... HIV detection using INSTI HIV-1/HIV-2 Antibody Test was accepted for presentation at the ... in Vancouver. The results will be presented Wednesday, July 22nd from 1:00 pm ...
(Date:7/7/2015)... , July 7, 2015  Neogen Corporation (NASDAQ: ... an agreement to expand its relationship with Illumina (NASDAQ: ... genomics. Under the agreement, Illumina will market and sell ... Infinium ® BeadArray technology, to the global agrigenomics ... agrigenomic customers through its GeneSeek ® genomics laboratory ...
(Date:7/7/2015)... July 7, 2015   Moleculera Labs ... matching grant from the Oklahoma Center for the ... supports the development and clinical validation of new ... neuronal antigens in patients experiencing neuropsychiatric disorders such ... are intended to assist physicians in identifying the ...
(Date:7/7/2015)... ... , ... The global aptamers market is expected to reach ... of 17.89% between 2015 and 2020. The aptamer type segments included in this ... report is segmented into diagnostics, therapeutics development, R&D, and other applications. Diagnostics applications ...
Breaking Biology Technology:bioLytical to Present Findings of Early HIV Detection 2bioLytical to Present Findings of Early HIV Detection 3Neogen signs commercialization agreement with Illumina 2Moleculera Labs Receives Grant from OCAST to Develop Assays to Identify Individuals with Neuropsychiatric Disorders of Autoimmune Origin 2Moleculera Labs Receives Grant from OCAST to Develop Assays to Identify Individuals with Neuropsychiatric Disorders of Autoimmune Origin 3Aptamers Market Growing at 17.89% CAGR to 2020 – New Research Available at RnRMarketResearch.com 2Aptamers Market Growing at 17.89% CAGR to 2020 – New Research Available at RnRMarketResearch.com 3Aptamers Market Growing at 17.89% CAGR to 2020 – New Research Available at RnRMarketResearch.com 4Aptamers Market Growing at 17.89% CAGR to 2020 – New Research Available at RnRMarketResearch.com 5
... earnings from continuing operations during the first ... million US dollars ... All amounts in US dollars, QUEBEC CITY, May 6 /PRNewswire-FirstCall/ ... of,added value products for health and nutrition industries, announced today,his financial results ...
... MYERS, Fla., May 5 NeoGenomics, Inc. (OTC,Bulletin Board: NGNM) ... financial results on Wednesday, May 7, 2008., The ... their,Q1 08 results on May 7, 2008, at 11:00 AM ... 689-8565 (international) at least,five minutes prior to the call. ...
... 5 /PRNewswire-FirstCall/ - GeneNews Limited (TSX: GEN), a,company ... early,detection of diseases and personalized health management, today ... its Board of,Directors, Mr. Harry A. Glorikian and ... James Howard-Tripp, Mr. Garth MacRae, Dr. Heiner Dreismann, ...
Cached Biology Technology:Atrium shows a strong financial performance for its first quarter 2Atrium shows a strong financial performance for its first quarter 3Atrium shows a strong financial performance for its first quarter 4Atrium shows a strong financial performance for its first quarter 5NeoGenomics Schedules Its Q1 2008 Earnings Release for May 7, 2008 2Genenews adds two members to its Board of Directors 2
(Date:6/17/2015)... , Deutschland und GERMANTOWN, Maryland , ... ®   Produktlinie mit DNA-Tests verbessert ... N.V. (NASDAQ: QGEN ; Frankfurt Prime Standard: QIA) ... neue STR-Testkits der Produktlinie Investigator ® ... den Markt eingeführt. Die neuen Kits zur Erstellung genetischer ...
(Date:6/16/2015)... June 16, 2015 /CNW Telbec/ - handyem Inc. ... around the incorporation of handyem,s HPC-150 portable flow ... the Mo-POD™. This unprecedented model of mobile laboratory ... at the Pennsylvania Convention ... 15 th to 18 th 2015. ...
(Date:6/15/2015)... According to a new market ... Statistical, and Hybrid), Technologies (Recognition, IVR, OCR, Pattern & ... MarketsandMarkets, The Natural Language Processing Market is expected to ... for the forecast period 2015-2020. Browse ... igures spread   through 155 P ages and ...
Breaking Biology News(10 mins):QIAGEN bringt in den USA neue Kits für die forensische DNA-Analyse auf den Markt 2QIAGEN bringt in den USA neue Kits für die forensische DNA-Analyse auf den Markt 3QIAGEN bringt in den USA neue Kits für die forensische DNA-Analyse auf den Markt 4QIAGEN bringt in den USA neue Kits für die forensische DNA-Analyse auf den Markt 5QIAGEN bringt in den USA neue Kits für die forensische DNA-Analyse auf den Markt 6handyem and FlowMetric Diagnostics announce their partnership in the development of Flow Cytometry- Based Solutions in diagnostic capabilities 2handyem and FlowMetric Diagnostics announce their partnership in the development of Flow Cytometry- Based Solutions in diagnostic capabilities 3Natural Language Processing Market Worth $13.4 Billion by 2020 2Natural Language Processing Market Worth $13.4 Billion by 2020 3Natural Language Processing Market Worth $13.4 Billion by 2020 4Natural Language Processing Market Worth $13.4 Billion by 2020 5
... new spring leaves up to 17 days earlier in the ... rise, according to a new study by Princeton University researchers. ... of northeastern forests and give a boost to their ability ... role in taking up carbon dioxide from the atmosphere, so ...
... reefs build their structures by both producing and accumulating ... and continued vertical growth capacity of reefs. An international ... carbonate being added by Caribbean coral reefs is now ... in some habitats is as much as 70% lower. ...
... have been named Charter Fellows of the National Academy ... and technological innovation. UH faculty members Benton Baugh, ... physics professor and chief scientist of the Texas Center ... professor in chemical and biomedical engineering, are among 101 ...
Cached Biology News:Spring may come earlier to North American forests 2Spring may come earlier to North American forests 3New evidence highlights threat to Caribbean coral reef growth 2New evidence highlights threat to Caribbean coral reef growth 3National Academy of Inventors honors 3 University of Houston professors 2National Academy of Inventors honors 3 University of Houston professors 3
Umbilical cord blood mesenchymal stem cells, For immunohistochemistry (IHC) Cell Chip with Human Umbilical Cord Blood Progenitor Cells...
Human peripheral blood CD19+ B cells, For immunohistochemistry (IHC) Cell Chip with Human Peripheral Blood Monocytes, B Cells, NK Cells and Stem Cells...
Umbilical cord blood CD14+ Monocytes, For immunohistochemistry (IHC) Cell Chip with Human Umbilical Cord Blood Monocytes, B Cells and NK Cells...
Umbilical cord blood basophils, For immunohistochemistry (IHC)...
Biology Products: